Last reviewed · How we verify
NCT04479826
Unannounced Meal Handling of Advanced Closed Loop Insulin Delivery in Monitored Condition
NA trial testing Advanced hybrid closed loop system in type1diabetes in 15 participants. Completed in 16 July 2021.
16 July 2021
Quick facts
| Lead sponsor | Sheba Medical Center |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 15 |
| Start date | 16 July 2020 |
| Primary completion | 16 July 2021 |
| Estimated completion | 16 July 2021 |
| Sites | 1 location across Israel |
Drugs / interventions tested
- Advanced hybrid closed loop system
Conditions studied
- type1diabetes — all drugs for type1diabetes →
Sponsor
Sheba Medical Center
Who can join
Adults 20 to 70, any sex, with type1diabetes. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study will follow participants for the periods of 3 months while using an advanced hybrid closed loop algorithm in free living conditions . Each period will have a different meal handling protocols. The objective is to identify the mitigation of the algorithm with different meal handling approaches.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Unannounced Meal Challenges Using an Advanced Hybrid Closed-Loop System.
Shalit R, Minsky N, Laron-Hirsh M, Cohen O, et al · · 2023 · cited 41× · PMID 37335759 · DOI 10.1089/dia.2023.0139
Verify or expand the search:
- PubMed search for NCT04479826
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Advanced hybrid closed loop system
Trials testing the same drug.
- NCT04901143 — Meal Handling of Advanced Closed Loop Insulin Delivery. · NA · completed
Other recruiting trials for type1diabetes
Currently open trials in the same condition.
- NCT06315127 — The CanDo (Canadian Donor Milk) Trial · NA · active not recruiting
- NCT05756829 — Type 1 Diabetes Virtual Self-management Education and Support · NA · recruiting
- NCT05421715 — Remote Digital Care Effects in Adolescents With Type 1 Diabetes · NA · recruiting
- NCT05454176 — Diabetes in African Youth · Phase 4 · recruiting
- NCT04593888 — Gluten Reduction and Risk of Celiac Disease · NA · active not recruiting
Other Sheba Medical Center trials
Trials by the same sponsor.
- NCT07401524 — Carbetocin Uterotonic Treatment in Twin Pregnancies for Prevention of Postpartum Hemorrhage · Phase 4 · not yet recruiting
- NCT07523373 — Facial Nerve Monitoring During Parotid and Facial Surgery Using a Non-Invasive Patch · NA · not yet recruiting
- NCT07509229 — 9-cis Beta-Carotene-Rich Extract of Dunaliella Alga in Retinitis Pigmentosa Patients · Phase 1, PHASE2 · not yet recruiting
- NCT07405723 — Arm Position and Blood Pressure Measurement Accuracy During Pregnancy · NA · recruiting
- NCT07474987 — Portable VR-based Chromatic Pupilloperimeter for Diagnosis and Monitoring of Traumatic Brain Injury · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04479826 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sheba Medical Center
- Last refreshed: 12 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04479826.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing